Loes van Schie

This paper presents a yeast-based platform for producing stable and potent heavy chain-only antibodies, demonstrating its effectiveness with an anti-SARS-CoV-2 example.

This study identifies optimal sites for introducing N-glycans on VHH antibodies to enhance macrophage delivery, demonstrating glycan-dependent uptake in vitro and in vivo.

The paper develops an open-source yeast chassis, OPENPichia, for synthetic biology by reverse engineering and characterizing industrial Pichia strains.

The paper describes the development of a broadly neutralizing antibody, XVR011, effective against SARS-CoV-2 and its variants in animal models.